. However, even if thrombotic events are not detected, coagulation parameters are often increased in cancer patients, and platelet turnover is generally enhanced. These clinical observations indicate a potential relationship between the blood coagulation system, platelet functions and cancer spreading via the bloodstream. To investigate whether a functional relationship might exist between platelet activities and tumour progression, experimental models have been developed to understand how specific platelet functions might contribute to this process. Analytical animal models in which specific platelet functions were altered through drug treatment or controlled genetic ablation have yielded evidence that platelets can guard tumour cells from immune elimination within the circulatory system, promote tumour cell arrest within the vasculature and affect tumour cell survival, thereby supporting the establishment of secondary lesions.
In this Opinion article, we highlight evidence indicating that the activation of platelets and the coagulation system have a crucial role in the metastatic progression of cancer. Insight from studies pointing to the contribution of platelets to tumour cell survival and spreading supports the notion that platelets are important, if not essential, in the development of metastases from the bloodstream. Existing knowledge and further mechanistic studies might suggest platelets and their functions as a new avenue for antimetastatic therapy.
Metastasis, platelets and haemostasis
Tumour metastasis to distant organs depends on interactions between tumour cells and the host microenvironment within the circulation, lymphatic vessels and target tissues. This involves blood cells, components of the coagulation system, stromal cells and the extracellular matrix. Cells within the bloodstream that contribute to metastasis are endothelial cells, platelets, lymphocytes, macrophages, mast cells, fibroblasts and bone marrow-derived progenitor cells 5 . The link between platelets and cancer was first documented in the mid-nineteenth century by Trousseau, who diagnosed himself and his patients with excessive blood clotting, which was caused by occult carcinoma that led to the inflammation of blood vessels 6 . He observed an association between thrombosis and cancer, and proposed that changes to the haemostatic system support the progression of the malignancy 7 . These initial findings suggested that tumours that are capable of activating platelets and forming clots are likely to spread and have a poor outcome. It is now well recognized that in cancer patients, tumour growth is accompanied by the development of an increased tendency towards blood clotting (hypercoagulable state), platelet abnormalities and an increased risk of thromboembolic disease 1, 4 . Moreover, thromboembolism is an early diagnostic feature 4 and a major cause of death 8 . Platelet activation is amplified in many cancers and found within the tumour vasculature [9] [10] [11] [12] . Platelet counts commonly vary during cancer progression and may predict the clinical outcome. Thrombocytosis (high platelet count) associates with poor prognosis in colon, breast, lung, gastric, renal, cervical, pancreatic, endometrial, brain and ovarian cancers 9, [13] [14] [15] [16] [17] [18] [19] . Thrombocytopenia (low platelet count) also occurs, but is mostly associated with chemotherapy that suppresses platelet production in the bone marrow 20 . The basic biological functions of platelets in coagulation and haemostasis (FIG. 1) are enacted during tumour metastasis. Platelets (also known as thrombocytes) are small, specialized blood cells that are released as anuclear cytoplasmic bodies from megakaryocytes in the bone marrow. One litre of blood contains about 400 billion circulating platelets that are turned over every week. The main function of platelets is to halt haemorrhage after tissue trauma and vascular injury 21, 22 . This is initiated through platelet activation, which results in adhesion and the release of a multitude of bioactive factors from platelet granules. This process leads to the firm attachment of platelets to the injured vessel wall and to the formation of a platelet aggregation-induced thrombus to seal the wound. Interaction between platelets and damaged endothelium or the subendothelial matrix initiates transient platelet adhesion. Binding of platelet receptors such as glycoprotein VI (GPVI) and glycoprotein Ibα (GPIbα) to exposed collagen and von Willebrand factor (VWF), respectively, leads to the activation of platelet integrin αIIbβ3 (also known as glycoprotein IIb/IIIa (GPIIb/IIIa)), which enables firm adhesion Nature Reviews | Cancer and platelet aggregation. The serine protease thrombin, which is generated from its latent form in plasma (prothrombin), triggers a strong procoagulant response by fully activating platelets and converting fibrinogen into crosslinked fibrin. This maximizes local thrombus formation and the release of platelet granules that contain active proteases, growth factors, matrix proteins and chemokines.
Components of the extrinsic haemostatic pathway, in particular coagulation factor VII (FVII) and tissue factor, are dramatically activated in cancer patients 23 .
Tissue factor that is expressed by tumour cells interacts with coagulation factor VII (FVII) and coagulation factor X (FX), and generates thrombin to enhance tumour progression 24, 25 . Thrombin not only leads to fibrin formation and the activation of platelet receptors that promote thrombosis, but also supports tumour cell malignancy [26] [27] [28] . Thus, tissue factor and thrombin have crucial roles in tumour growth, angiogenesis and metastasis. These processes have been reported in an extensive body of literature and were covered by other reviews [29] [30] [31] .
A resurgence of interest in the field refined the original hypothesis of platelet involvement in tumour metastasis, on the basis of the use of transgenic animal models; thereby tying in a broader knowledge and renewed appreciation of platelets as an important part of the host microenvironment 5, [32] [33] [34] [35] [36] (TABLE 1) . Investigation led to a model of platelet-supported tumour metastasis in which tumour cells enter the bloodstream (intravasation), and bind and activate platelets (cohesion) and leukocytes. Evidence is emerging that these host cells then assist tumour cell arrest at the vessel wall (adhesion) and survival within the vasculature (immune evasion), which enables exit from the circulation (extravasation), and tumour cell survival and proliferation within target tissues of metastasis 8, [37] [38] [39] [40] . In making this argument, we recognize that there are still many opportunities for research into the role of platelets and that, in many cases, evidence is still needed. However, on the basis of reported results, we suggest that the haemostatic properties of platelets crucially contribute to metastasis and should be considered in cancer treatment and targeted therapy.
Angiogenesis and vascular remodelling
Vascularization within a tumour is a portal through which tumour cells can enter the bloodstream to disseminate. Platelets may stabilize vessel growth during tumour development and thus contribute to this process.
As tumours and metastases expand, they must recruit new blood vessels to provide nutrients and oxygen for further lesion growth. Blood vessel formation within tumours is called angiogenesis. Angiogenesis was originally hypothesized by Judah Folkman 41 as a necessary mechanism for tumour progression to prevent hypoxia-induced growth stagnation and necrosis. The finding that platelets release vascular endothelial growth factor (VEGF) on activation was the first evidence that platelets promote angiogenesis 42 . Platelets were then formally hypothesized by Folkman and colleagues 43 to contribute to tumour angiogenesis. Even though platelets are poised to alter the tumour vasculature 9 , initial evidence in mouse models remains equivocal.
Platelets contain many factors that are released during platelet activation and that regulate the angiogenic process. These factors are anti-angiogenic (such as angiopoietin 1 (AnGPT1; also known During thrombus formation, thrombin activates G protein-linked protease-activated receptors (PArs) at the platelet surface, thereby triggering a flux in intracellular calcium and a decrease in cyclic AMP (cAMP). This allows the rapid reorganization of the platelet cytoskeleton and shape change, maximizing platelet adhesion during thrombus formation. Other platelet agonists include collagen of the subendothelial matrix that is exposed during vascular injury, ADP and thromboxane A2 (TXA2). TXA2 binds G protein-coupled receptors P2Y and TBXA2r to stimulate platelet degranulation and the release of their contents, respectively, as part of an amplification loop of platelet activation and aggregation. For example, thrombosis is perpetuated by prothrombin, fibrinogen, von Willebrand factor (vWF), platelet factor 4 (PF4), P-selectin, TXA2 and ADP 21, 22 . Platelets are now also recognized as modulators of endothelial integrity and immune cell trafficking between the bloodstream and sites of inflammation through their released factors 45, 152 . Platelets sustain vascular stability through the maintenance of endothelial cell junctions via the release of brain-derived neutrophic factor (BDNF), epidermal growth factor (EGF), sphingosine 1-phosphate (s1P), angiopoietin 1 (ANGPT1) and platelet-activating factor acetylhydrolase (PAF) 152 . Activated platelets dispense interleukin-8 (iL-8), iL-1β, c-c motif chemokine 5 (ccL5; also known as rANTEs), cD40 ligand (cD40L) and histamine that stimulate endothelial cells to upregulate adhesion receptors and chemokine release to promote leukocyte recruitment and tissue infiltration during the inflammatory response 22, 153 . The potential role of platelets in cancer progression and target organ colonization by circulating tumour cells is summarized in this article.
AnG1), sphingosine 1-phosphate (S1P), serotonin, thrombospondin 1 (THBS1)); or are pro-angiogenic (such as VEGFA, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF; also known as FGF2)); or function as cytokines (such as interleukin-1β (Il-1β) and Il-8); or function as proteases (such as matrix metalloproteinase-2 (MMP2) and MMP9) 44, 45 (TABLE 2). Platelet activation can occur locally within the tumour vascular environment, as well as systemically, as seen in patients with prostrate, breast, lung, colon or gastric cancer 8 . The leaky tumour vasculature may expose matrix proteins such as collagen, which is a potent activator of platelets. Tumour cells could function indirectly through binding of VWF to initiate platelet tethering, given that VEGF stimulates VWF secretion by endothelial cells 46 . Furthermore, systemic deployment of C-X-C motif ligand 12 (CXCl12; also known as SDF1) from platelets regulates neoangiogenesis through the recruitment of haematopoietic progenitors 47 . Owing to the regulatory effect of platelets on vascular remodelling, they were surmised to help to shape the tortuous vasculature within tumours. Platelets have been proposed to alter blood vessels through the localized release of platelet factors 43 . Interestingly, platelets have compartmentalized pro-angiogenic and anti-angiogenic α-granules, which may be differentially released depending on the stimuli. For example, granules laden with VEGF are selectively released after ligation of protease-activated receptor 1 (PAr1), and granules containing endostatin are released on PAr4 activation 48, 49 . These findings not only explain a pivotal role of platelets in regulating haemostasis, but also suggest that tumour cells could use platelets to balance an angiogenic milieu. In a similar way to platelet-derived lysophosphatidic acid (lPA) enhancing bone metastatic growth and progression 50 , platelet-released factors may have a role in tumour progression, and therefore warrant further investigation. The attenuated tumour growth that is observed in P-selectin-deficient mice 51 could affect metastasis on the basis of the impaired recruitment of leukocytes, although the contributions of endothelial and platelet P-selectin are indiscriminate. By contrast, an initial study demonstrates that the transplantation of wild-type bone marrow into thrombospondin 1-deficient mice resulted in diminished tumour growth 52 . This implies that platelet delivery of an angiogenesis inhibitor might suppress tumour progression. nonetheless, there is no change in tumour growth in mice deficient in fibrin, platelet activation or GPVI expression, and there are no overt vascular differences from the wild-type mice [53] [54] [55] . Fundamental questions of how platelets affect tumour angiogenesis, and in which way their pro-angiogenic or anti-angiogenic capacities contribute to tumour progression remain to be further investigated.
A recent study provides evidence that platelets prevent haemorrhaging within a tumour 56 , indicating that the haemostatic functions of platelets are probably crucial for maintaining vascular integrity in tumours. Antibody-induced thrombocytopenia in mice was immediately followed by erupted haemorrhage within tumours, which resulted in reduced tumour cell proliferation and increased apoptosis 56 . The severe bleeding could be rescued by reconstitution with resting platelets, but not with platelets that were experimentally exhausted of their granule content after ex vivo thrombin activation. This indicates that the secretion of platelet granules is crucial for platelet regulation of tumour vascular homeostasis. It would be interesting to study further the resulting effect on tumour growth. It was proposed that platelets stabilize the tumour vasculature through anti-angiogenic factors, such as AnGPT1 and serotonin, which presumably counteract VEGFA that is released from the tumour cells 56 . Another possibility is that platelets dampen inflammation and local tissue damage through the modulation of leukocyte recruitment or cytokine release 57 . Therefore, tumours may develop a dependence on platelets for preventing haemorrhage during tumour growth and angiogenesis.
Although platelet factors help to regulate tumour blood vessel integrity; surprisingly, adhesive platelet functions and thrombus formation are apparently not required 58 . Mice deficient in platelet GPIbα, VWF and P-selectin or in integrin αIIbβ3 did not show tumour haemorrhaging. However, angiogenesis analysed in the cornea of the eye clearly involved platelet adhesion to prevent haemorrhage, as seen in mice rendered thrombocytopenic or in mice lacking platelet receptor GPIbα 59 . Supporting this premise, previous in vivo imaging of platelets in tumours showed platelet rolling along the endothelium, but neither firm adhesion nor thrombus formation within the tumour microcirculation 60 . The slowed blood flow within tumours may allow for localized platelet granule release 43, 58 and might not require the involvement of receptors and 
• immune competent host αiibβ 3 on platelets supports bone metastasis 95 Gαq, guanine-nucleotide-binding protein G q ; GPibα, glycoprotein ibα; GPvi, glycoprotein vi; LPA, lysophosphatidic acid; NFE2, nuclear factor erythroid-derived 2; PAr4, protease-activated receptor 4. ligands that mediate platelet adhesion under higher shear conditions. Although platelets and their haemostatic functions affect vascular integrity and remodelling within tumours, there is no direct evidence that platelets also affect tumour cell intravasation and access to the circulation. As the molecular mechanisms through which platelets contribute to primary tumour growth and angiogenesis still need to be explored further, convincing evidence already indicates a crucial role of platelets in promoting tumour cell metastasis from the bloodstream (FIG. 2) .
Tumour cell survival in the bloodstream
The microenvironment within the bloodstream is hostile for circulating tumour cells and their survival before extravasation is crucial for metastasis. Antibody-induced 61 or genetic 62 depletion of platelets inhibits metastasis, whereas platelet reconstitution restores metastatic activity 63 , as seen in several independent mouse models. A definitive study explored a model that lacks circulating platelets based on nuclear factor erythroid-derived 2 (nFE2) knockout, which interrupts platelet production by interfering with megakaryocyte maturation 62 (TABLE 1) . Experimental metastasis is nearly completely inhibited in these mice. These results, together with reduced metastasis in PAr4-knockout mice and fibrinogen-knockout mice, indicate that platelets and their activation have an essential role in haematogenous tumour cell spreading and that this process involves thrombin-dependent and thrombinindependent mechanisms 62 . Platelets of Par4 -/-mice are unable to aggregate in response to thrombin, but their thromboxane and GPVI receptors are not disturbed 62, 64 . Treatment with the thrombin inhibitor hiruidin further reduces metastasis in PAr4-null mice, implying a mechanism that involves other thrombin ligands, such as fibrinogen 65 or PArs expressed by the tumour cells. In fact, host deficiencies in PAr1 and PAr2, in which endothelial responses to coagulation proteases -but not those of the experimentally introduced tumour cells -are attenuated, did not provide protection against metastasis 62 . Thrombin activates PAr1 and PAr2 receptors that are expressed by host and tumour cells, and generally supports tumour growth, angiogenesis and metastasis 66, 67 . Mechanisms by which platelets assist haematogenous metastasis depend on the ability of platelets to function together with coagulation factors in protecting tumour cells within the bloodstream. When proteases of the hierarchical coagulation cascade activate thrombin, this protein cleaves fibrinogen and induces fibrin formation. During this process, platelets crosslink through adhesion molecules, such as integrin αIIbβ3, which, once activated, binds soluble fibrinogen, and supports thrombus formation and platelet incorporation into fibrin clots. newly activated platelets perpetuate thrombosis with the discharge of additional fibrinogen, VWF and fibronectin. Early observers showed that entanglements of platelets and fibrin surround tumour cells that are arrested within the vasculature [68] [69] [70] . leukocytes and natural killer (nK) cells are found in close proximity to these metastasizing cells 71 . nK cells can disable blood-borne cancer cells by direct contact and lysis. However, the adhesion of platelets to tumour cells and their incorporation into platelet heteroaggregates may shield the tumour cells from nK cell activity. This could explain why the clearance of circulating tumour cells by nK cells is incomplete and allows cancer spreading from the bloodstream 72 . Furthermore, the incorporation of plasma fibronectin into fibrin clots enhances metastasis to the lungs, but less so to other sites, as seen in mice that were postnatally depleted of the plasma fibronectin gene in the liver 73 . The involvement of nK cells and haemostatic factors in metastasis was explored through the development of new mouse and cell models 74 . Platelets and tissue factor, and thus thrombin generation, were clearly identified as nodes in the effect that nK cells exert on the metastatic process. Fibrin deposition, which is induced by tumour cell-associated tissue factor, impedes tumour cell recognition by nK cells and thereby enhances metastasis through cloaking tumour cells within the circulation 53, 75 . This concept is based on studies of experimental and spontaneous metastasis in mice that lack Gαq, fibrinogen or nK cells (TABLE 1) . Mice lacking the α-subunit of the heterotrimeric guaninenucleotide-binding protein G q (Gαq), a 
Integrin αvβ3 protein important for platelet activation, were mostly unable to support metastasis after tumour cell injection into the venous circulation. Spontaneous metastasis from primary subcutaneous tumours was also attenuated, although tumour growth itself was not affected. Similar results were seen in fibrinogen-deficient mice and in another study using mice treated with an inhibitor of platelet aggregation 53, 76 . In the presence of nK cells, platelet activation is required for tumour cell survival. notably, the blocking of metastasis by Gαq or fibrinogen knockout was abrogated when nK cells were immunologically or genetically depleted. This clearly indicates that the supportive effects of platelet activation and fibrinogen involve tumour cell shielding from nK cell function (FIG. 2) .
The same group later recognized nK cell-independent mechanisms that determine early tumour cell survival in the target organ microvasculature. However, it was clearly documented that even nK-independent survival requires thrombin generation 53, 75 . In an elegant approach, tumour cells were generated from murine fibroblasts of tissue factordeficient embryos by transformation with HrAS. Tumour growth and metastasis of these cells were then studied in immunocompetent mice which either were lacking in tissue factor, Gαq, fibrinogen and nK cell function, or were severely depleted of prothrombin 75 . results from this model indicated that tumour-associated tissue factor and distal components of the haemostatic system are important, but not crucial, for initial tumour cell localization in the lung microvasculature. However, genetic reduction of prothrombin profoundly reduced the survival of the lodged tumour cells, and thereby determined early success of metastasis development 75 . Together, these findings suggest that the plateletfibrin axis plays an important part in immune evasion. Platelets also contribute to nK cell-independent intravascular tumour cell survival. The exact mechanisms of how platelet activation and fibrin clotting protect from nK cells still need to be defined. Current hypotheses include that platelets provide a physical barrier to nK cell contact, and that platelets exert paracrine suppression of nK-mediated cytolytic activity 78 . A recent study illuminated one such mechanism by demonstrating that transforming growth factor-β (TGFβ) from platelets diminishes nK granule mobilization, cytotoxicity and interferon-γ (IFnγ) secretion 79 . Several other soluble mediators that were suggested to participate, including prostaglandin E 2 (PGE 2 ), need to be studied for this capacity 78 . Overall, the ability of platelets to induce the formation of heteroaggregates between tumour cells, platelets and leukocytes may play an important part in determining tumour cell survival within the microvasculature of target organs of metastasis.
Tumour cell and vascular interactions
Transient interactions. The process of tumour cell arrest within the microvasculature of target organs is difficult to study because these adhesive events are rare in a living host. Therefore, tumour cell arrest As platelets become activated, they undergo a shape change, increase their adhesiveness, release granules and microparticles, and perpetuate the cohesion of heteroaggregates containing tumour cells, platelets and leukocytes. Platelet granules contain growth factors, chemokines and proteases. During cohesion, circulating tumour cells can interact with activated platelets and leukocytes, and form heteroaggregates that support attachment to the endothelium and thereby contribute to metastasis. During coagulation, platelet-initiated coagulation steps can activate receptors on tumour cells (for example, protease-activated receptor 1 (PAr1) and PAr2) and promote the release of tissue factor that further enhances procoagulant activity. During adhesion, initial, transient adhesion involving selectins, mucins, cD44, and other sialyl Lewis X/A-containing glycoconjugates is followed by firm attachment that is mediated by integrins and intercellular cell adhesion molecules. During immune evasion, multivalent plasma proteins form intercellular bridges, and activated platelets and fibrinogen protect tumour cells from natural killer cell lysis during haematogenous metastasis. coincidently, tissue factor and Fviia activate thrombin to cleave PArs on platelets and tumour cells to promote invasion and metastasis. GP, glycoprotein; icAM, intercellular adhesion molecule; PAr, protease-activated receptor; PsGL1, P-selectinglycoprotein ligand 1; sLe a , sialyl Lewis a antigen; sLe in vivo cannot be analysed as reliably and quantitatively as the attachment of circulating leukocytes during inflammation. Furthermore, in vitro models can mimic the complexity of the intravascular situation only in certain aspects. nevertheless, studies focused on tumour cell interaction with vascular cells at early time points after introducing malignant cells into the circulation of drug-treated or genetically altered animals have shed light on tumour cell arrest in target organ vessels 51, 80 . These approaches have also yielded information on adhesion receptors and ligands that mediate tumour cell anchorage at the endothelium and the subsequent early events of metastatic colonization, as summarized below.
Evidence suggests that the rolling and tethering of circulating tumour cells to the vessel wall, and the formation of heteroaggregates between tumour cells, platelets and leukocytes can be mediated by selectins, a family of transmembrane cell adhesion molecules. Selectins enable white blood cell trafficking by promoting their transient adhesion within the bloodstream during inflammation. Selectins are expressed by platelets, endothelial cells and leukocytes. Metastasis studies indicate that platelets can use selectins to support initial transient tumour cell interaction with the endothelium in a manner similar to that observed during the recruitment of leukocytes in inflammation 81 (FIG. 2) .
Selectins contain a conserved lectin domain that recognizes and binds glycoconjugates on other cells 81 . All selectins recognize ligands that contain tetrasaccharide sialyl lewis x and lewis a antigens 82 , and can require the clustering of selectin molecules for high-affinity binding 81 . Some of these glycoconjugate ligands include P-selectinglycoprotein ligand 1, mucins and CD44 variants, many of which are expressed by metastatic tumour cells 82 . There are at least three selectin types. l-selectin is constitutively expressed on leukocytes; E selectin and P-selectin are present on endothelial cells and platelets, respectively, but only when these are activated. On activation, P-selectin translocates to the cell surface from WeibelPalade bodies in endothelial cells, and from α-granules in platelets.
results from P-selectin-knockout mice established on an immunodeficient background indicated that tumour growth and metastasis of colon carcinoma cells involves P-selectin function and platelets. This was clearly evident at early steps of tumour cell interaction with the pulmonary microvasculature during metastasis 51, 83 . P-selectin on endothelial cells was also shown to contribute to experimental metastasis, as seen in irradiated wild-type mice after reconstitution with P-selectin-deficient bone marrow 84 . In this study, intravascular tumour cell rolling and metastasis were attenuated, but not as strongly as in P-selectin-null mice (TABLE 1) . Therefore, this model allowed the dissection of the contributions of P-selectin on endothelial cells and platelets to metastasis 84 . Metastasis can also be attenuated by the anticoagulant heparin. In addition to inhibiting thrombin, heparin binding can mimic negatively charged mucins at the tumour cell surface 71 . Thus, heparin impedes tumour cell binding to P-selectin on platelets 29, 71, 85, 86 . P-selectin-dependent tumour cell tethering is partly mediated through binding to tumour cell mucins, which also induce platelet aggregation 51, 83 . These interactions were demonstrated using co-cultures of platelets, colon carcinoma mucins and activated endothelium. The results may be relevant to human colon carcinomas that express mucin-type P-selectin ligands. non-mucin ligands of l-selectins and P-selectins function synergistically to enhance metastasis through tumour cell binding to leukocytes and platelets 87 . In static co-cultures of tumour cells, platelets and leukocytes, selectin-dependent interaction between these cell types induces the activation of endothelial cells to release C-C motif chemokine 5 (CCl5; also known as rAnTES). In vivo, CCl5, which is probably expressed by activated endothelium, recruits monocytes to further increase metastasis 88 . Therefore, these findings suggest that platelet-dependent activation of endothelial cells is required for monocytes to home to, and promote the development of, the micrometastatic niche. under shear stress that is generated by blood flow, CD44 is a dominant ligand on colon cancer cells that mediates their binding to platelet P-selectin. This engagement can be competitively inhibited by fibrin, but not by fibrinogen 89 . Evidence supports that CD44-fibrin interaction helps to establish firm adhesion between platelets and tumour cells. Thus, a model emerges in which tumour cells recruit platelets and leukocytes to form heteroaggregates, which may travel within the circulation and then tether and roll along activated areas of the endothelium in a P-selectin-dependent manner. The tethering process precedes higher affinity adhesion and tumour cell arrest 90 as a prerequisite for extravasation from the bloodstream. 
Disseminated intravascular coagulation
Pathological activation of coagulation (blood clotting) mechanisms that leads to the formation of small blood clots in blood vessels throughout the body.
Endothelial retraction
Disruption of adherens junctions of endothelial cells creates gaps in the endothelial monolayer and increases vascular permeability while exposing the matrix proteins of the basement membrane.
Glycoconjugates
Carbohydrate-linked lipids and proteins, which include receptors and ligands that function as cell adhesion molecules.
Migratory thrombophlebitis
Malignancy-associated hypercoagulable state leading to spontaneous platelet-rich clots in veins anywhere in the body that dynamically form, resolve and reappear.
Paraneoplastic disease
Disease induced as a result of tumour burden; generally caused by the release of tumour-derived hormones, peptides or cytokines, or by the misguided destruction of normal tissue by immune cells targeted against malignant cells.
Pulmonary embolism
Blockage of the main artery of the lung or one of its branches by a platelet-rich clot that originated in the venous circulation and dislodged from where it initially formed.
Shear stress
The velocity of flowing blood is highest in the centre of vessels and decreases towards the vessel wall, resulting in differential flow that generates a shearing force.
Thromboembolic disease
Condition caused by travelling blood clots or emboli that occlude blood vessels; commonly manifesting as deep vein thrombosis or pulmonary embolism in cancer patients.
Weibel-Palade bodies
Secretory granules of endothelial cells that particularly store and secrete multimerized von Willebrand factor, and which translocate P-selectin to the membrane surface on cell activation. cells and avidly bind exposed subendothelial matrix proteins. In this process, platelets promote the selection of tumour cells with a metastatic phenotype (FIG. 2) .
The transition from selectin-dependent tumour cell rolling along the endothelium 90 to firm arrest is mediated by integrins. The main platelet integrin involved in this process is integrin αIIbβ3. In haemostasis, this receptor becomes activated in response to platelet agonist stimulation or platelet interaction with collagen at exposed sites of the subendothelial matrix. Activated integrin αIIbβ3 can bind soluble fibrinogen, which then forms inter-platelet bridges and leads to thrombus formation 91 (FIG. 1) . Fibrinogen also crosslinks tumour cells and platelets. Platelet integrin αIIbβ3 and tumour cell receptors, such as integrin αvβ3, mediate tumour cell-platelet cohesion that helps to overcome shear forces that are generated by blood flow, by lodging circulating tumour cells to the vessel wall 92 . Inhibitors of αIIbβ3 reduce tumour cell colonization; for example, of the lungs 63, 93 . This indicates that αIIbβ3 coordinates tumour cellplatelet cohesion and adhesion, which are important steps in metastasis. Tumour cell integrin αvβ3 then perpetuates adhesion, migration and invasiveness in cooperation with platelets 92, 94 . For instance, knockout mice lacking the β3 integrin subunit gene have reduced bone metastases and bone destruction. This is because platelet integrin αIIbβ3 is required for platelet aggregation and crucially contributes to the homing of metastatic cells to the bone microenvironment, where osteoclast integrin αvβ3 mediates bone destruction in growing metastatic lesions 95 . Evidence for platelet involvement in tumour cell lodging within target organ microvessels was obtained from lung preparations, which were isolated at early time points after tumour cell injection into the venous circulation and infusion with fluorescently labelled antibodies to identify the tumour cells, platelets and fibrin clots 80 . Tumour cells were found to have spread within pulmonary microvessels 2-6 hours postinjection, and they were associated with platelets and fibrin clots. Inhibition of clot formation with hirudin reduced tumour cell retention in the lung 80 . Platelets further support bone metastatic growth and cytokine-induced bone destruction by producing lPA in response to stimulation by tumour cells 50, 96 . The inhibition of platelet aggregation with Integrilin, an antagonist of platelet integrin αIIbβ3, blocks bone metastasis and thereby identifies platelets as a crucial source of lPA in the tumour microenvironment 50, 96 . Generally, cell attachment to the vessel wall depends on the affinity state of integrin adhesion receptors 97 . This is well established for platelets and leukocytes 91 . The specialized functions of these cells in the repair of vascular injury and inflammation require that the cells rapidly respond to local stimuli and engage in adhesive interactions that support their arrest at the vessel wall. Agonist stimulation leads to conformational changes of important integrins, such as αIIbβ3 on platelets, and αMβ2 and α4β1 on leukocytes, and transition of the receptors into a high-affinity state 98 . Once activated, the receptors can bind ligands from solution, leading to cell-cell cohesion and high-affinity interactions with ligands or counter receptors on endothelial cells and proteins of the subendothelial matrix [99] [100] [101] [102] . During metastasis, the activation of platelets, leukocytes and potentially tumour cells can support their cohesion and firm arrest at the vascular endothelium; this involves multiple receptors and ligands on each cell type. These include platelet integrin αIIbβ3, leukocyte β2 integrins and α4β1, tumour cell and endothelial cell β1 integrins and αvβ3, intercellular adhesion molecules ICAM, VCAM, as well as P-selectins, l-selectins and E-selectins 82 (FIG. 2) .
Analysing the adhesive behaviour of blood-borne tumour cells in a blood perfusion model revealed that tumour cells can also express key integrins, such as αvβ3, in distinct states of activation 103 . Only the high-affinity, activated form of αvβ3 on tumour cells mediates their interaction with platelets and supports tumour cell arrest during blood flow 103 . In this way, platelet-supported anchorage selects for a subpopulation of tumour cells that constitutively express the high-affinity form of αvβ3 (REF. 104 ). In subsequent steps of the metastatic cascade, this high-affinity receptor further promotes tumour cell invasion by enhancing protease activation [104] [105] [106] . Furthermore, the high-affinity form of tumour cell integrin αvβ3 stimulates tumour cell survival and proliferation in target organ tissues, as has recently been shown for breast cancer brain metastases 107 . Activated αvβ3 elicits brain lesion growth through continuous, hypoxiaindependent expression of tumour cell VEGF by inhibiting eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), which is a translational repressor 107 . Thus, platelet-mediated selection of tumour cells expressing a high-affinity receptor can identify a subset of tumour cells with an aggressive metastatic potential. Interestingly, some cancer patients apparently produce inhibitory antibodies against high-affinity αvβ3, which inhibit tumour cell platelet interaction and target organ colonization from the bloodstream 108 . These antibodies can also repress the growth of established, late-stage metastases 109 . In the absence of β3 integrin expression, alternative mechanisms can drive tumour growth and progression. For example, mammary carcinoma development and spontaneous lung metastasis were essentially unaffected in mice deficient for either the β3 and β5 subunit genes or a combination of both, when the disease was driven by the epidermal growth factor receptor 2 (ErBB2; also known as HEr2 and neu) oncogene 110 . Molecules mediating tumour cell migration and adhesion may also bind directly to counter-receptors on platelets. For example, at the leading edge of invasive cells, poliovirus receptor (also known as nectin-like molecule 5 (nECl5)) co-localizes with integrin αvβ3 (REF. 111 ). The nECl5 receptor on colon cancer cells enhances experimental metastasis in a platelet-dependent manner. This process involves adhesion to a counter-receptor on platelets and thereby indirectly enables tumour cell attachment to the vascular endothelium. Although intriguing, this mechanism awaits further investigation 111 .
Involvement of the subendothelial matrix.
Another important platelet adhesion receptor that potentially contributes to tumour progression is the GPIb-IX-V receptor complex. In haemostasis, this complex is central to thrombus formation primarily in the arterial circulation.
The interaction between platelet GPIbα
There are several important questions to be addressed: which stages of tumour progression are affected by platelet haemostatic functions? When are platelet adhesive functions important to support or influence tumour progression?
and VWF allows platelets to tether to the vascular endothelium, especially in the presence of high shear forces that are generated by arterial blood flow. This adhesion process enables platelets to recognize exposed sites of extracellular matrix, leading to platelet binding, activation and thrombus formation 21 . The importance of the extracellular arrangement of GPIbα in cancer progression is highlighted in several studies 112, 113 . It was demonstrated that experimental metastasis of melanoma cells is reduced in immunocompetent mice lacking GPIbα 112 . By contrast, wildtype mice treated with monovalent antibody fragments directed against GPIbα showed enhanced metastasis of the same melanoma cell type. However, no underlying mechanism was identified 114 . Platelet GPIbα might be involved in tumour progression in several different ways. The receptor can bind thrombin and VWF. Which ligand is important, and which step of the metastatic cascade may involve GPIbα binding of either of these ligands, still needs to be explored. For example, it was shown that VWF can actually inhibit experimental metastasis from the bloodstream 115, 116 , whereas thrombin clearly supports this process.
An important trigger of platelet interaction with the vessel wall is the exposure to subendothelial matrix proteins. When platelets encounter denuded sites of subendothelial matrix, they attach to these sites and become activated. During the metastatic process, microlesions in the endothelium could exist in the metastatic niche or be generated through leukocyteinduced or tumour cell-induced endothelial retraction. retraction exposes collagen, which is avidly recognized by platelet integrins, such as α2β1, as well as by the platelet glycoprotein receptor for collagen VI (GPVI) 21 . GPVI ligation causes platelet activation, aggregation and further amplifies platelet binding to collagen. Whether this mechanism contributes to tumour metastasis is still unclear, but tumour cell colonization of the lungs from the bloodstream was found to be reduced in GPVI-deficient mice 55 .
Extravasation
Platelets can modulate the permeability of the vasculature. Platelet-mediated enhancement of vascular permeability, for example, helps immune cells to colonize sites of inflammation. It is possible that platelets might similarly assist tumour cells to exit the bloodstream and enter target organs of metastasis. It is likely that such a process involves the release of platelet granules and mircoparticles
.
Platelets and blood vessel permeability.
Although the profuse release of adhesive molecules, cytokines and mitogens from platelet granules apparently contributes to the modulation of immune surveillance, it may also facilitate tumour cell extravasation, survival and growth, although this is currently mostly speculation. The integrity of the vascular endothelium within the microenvironment of attached tumour cellplatelet heteroaggregates may be directly, or indirectly, affected by growth factors released from platelet α-granules, including platelet-derived growth factor (PDGF), TGFβ, EGF, insulin-like growth factor 1 (IGF1) and VEGFA 44, 45 . Platelets also release the endothelial agonist S1P, a potent inhibitor of vascular leakage 117, 118 . In addition to S1P, platelets are major stores for lPA. Both S1P and lPA are signalling molecules that affect cytoskeletal rearrangement, actin changes, cell-cell communication, and that influence endothelial permeability. S1P decreases the permeability of endothelial cells, and lPA stabilizes the integrity of certain endothelial types 119, 120 . For example, lPA notably induces permeability in brain microvascular endothelial cells 121 . Thus, platelets may affect blood vessel integrity and could affect tumour cell extravasation.
Another potent bioactive factor that is released from platelets is serotonin. Platelets take up serotonin from plasma, store it in dense granules and release it upon activation. This leads to modulation of vascular tone, inducing either vasoconstriction or vasodilation 122 . The introduction of tumour cells into the circulation of mice can considerably increase plasma levels of serotonin 123 . The blockade of serotonin receptors or calcium channels hinders experimental tumour metastasis, as seen in the liver 123, 124 . This exemplifies another means by which interference with platelet activation can augment metastasis. An additional potent vasoactive and inflammatory factor that is released by platelets is histamine. Histamine increases vascular permeability and thus augments leukocyte extravasation. Moreover, platelets release CCl5, which recruits monocytes and eosinophils and triggers further histamine release 125 . Together, the integration of circulating tumour cells into plateletleukocyte heteroaggregates, arrested at the vascular endothelium, generates a rich microenvironment for the incorporated tumour cells that might enhance their extravasation and invasion of target tissues. These hypotheses have not yet been examined.
Therapeutic implications
Physicians currently administer anticoagulants to prevent and treat venous thromboembolism in cancer patients 126 . Going beyond the use of anticoagulants for prophylaxis in paraneoplastic disease, these compounds need to be further investigated for the treatment of tumour progression. low molecular mass heparin has the potential to do both 29, 85, 127 . Antithrombotic therapies such as aspirin, warfarin and cyclooxygenase (Cox) inhibitors can improve cancer patient survival in some cases. These agents have many targets, apart from tumour cells
Box 1 | platelet microparticles
When platelets are activated, they relinquish surface membrane particles (30-100 nm) and exosomes (100 nm-1 μm) that are derived from α-granules fused with the plasma membrane. Both particle types contain parent platelet membrane proteins and lipids 137 . Platelet microparticles have a range of surface receptors, including integrin αIIbβ3 (also known as glycoprotein IIb/IIIa (GPIIb/IIIa)), the GPIbα-IX-V receptor complex, P-selectin, C-X-C motif receptor 4 (CXCR4), bioactive lipids such as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), and cytoplasmic and secreted proteins. Furthermore, platelet microparticles provide a procoagulant membrane surface for the activation of thrombin 137 . Blood-borne microparticles are also formed from endothelial cells, leukocytes and tumour cells, and contribute to many pathological disease states, especially cancer 138, 139 . The association of platelet microparticles with individual circulating tumour cells or with tumour cells in heteroaggregates could potentially add to their expression of adhesion molecules, stimulate the release of cytokines and activate intracellular signalling pathways. As a consequence, downstream effects might alter the reactivity of blood-borne tumour cells with the vasculature, stimulate adhesion and the proliferation of cancer cells and affect metastasis. Preliminary studies demonstrate an increased invasiveness, migration, proliferation and experimental metastasis of tumour cells when incubated with platelet microparticles [140] [141] [142] [143] [144] . A mechanistic involvement of platelet microparticles in tumour progression has not been investigated in detail. However, high levels of these particles correlate with aggressive tumours and a poor clinical outcome [145] [146] [147] [148] [149] [150] [151] . P e r s P e c t i v e s nATurE rEVIEWS | CanCer VOluME 11 | FEBruAry 2011 | 131
(platelets predominantly express prostaglandin G/H synthase 1; also known as COX1) 85, 128, 129 , and bleeding side effects may occur. Antiplatelet drugs can reduce experimental metastasis in some animal models 8 . Furthermore, the use of mouse models to assess platelet function in human cancer is limited owing to species-specific differences. In particular, human platelets are primarily activated through the PAr1 thrombin receptor and co-activated by PAr4, whereas mouse platelets do not express PAr1 and are prominently activated via PAr4.
Platelets should be considered in the management and detection of human cancers [130] [131] [132] . The prometastatic properties of platelets raise questions of whether chemotherapy-induced thrombocytopenia and platelet restoration in these patients affect disease progression and outcome. Intriguingly, platelets specifically sequester regulators of angiogenesis (such as VEGF, platelet factor 4 (PF4) and THBS1) that are released from tumours, as seen in mouse models 52, 133, 134 . Increased levels of these factors are detectable in platelets, but not in plasma or serum, when dormant tumours are microscopic (<1 mm in size) 134 . Thus, tumour-associated alterations of platelet granule contents could be valuable biomarkers for cancer progression.
Antiplatelet drugs used for the intervention of cardiovascular disease, such as integrin αIIbβ3 antagonists, might be studied for their effects on tumour progression, metastasis and overall survival in clinical trials. Therapies targeting P-selectin 135 , GPIb-IX-V and GPVI could also be explored. Adverse effects owing to normal platelet physiology may be overcome by the targeting of pathological tumour cellplatelet interactions while maintaining normal platelet functions. So far, no specific platelet function targeted therapy has been included in standard cancer treatment. Furthermore, studies investigating possible links between heritable platelet dysfunctions in the human population and the incidence of metastatic disease have not been undertaken. The overall evidence from experimental models on the contribution of platelets to cancer progression, however, predicts that a better understanding of the molecular mechanisms of platelet involvement will help to identify promising new clinical approaches. perspectives This Opinion article highlights evidence for a role of platelets in tumour metastasis. Metastasis is a complex process and platelets may contribute to its success at distinct stages of progression. Before the onset of tumour cell dissemination, platelets may affect the development and architecture of the tumour vasculature. The most profound influence of platelets on metastasis probably occurs when tumour cells have entered the bloodstream. In that dynamic environment, platelet functions can affect the progression of haematogenous metastasis by complementing tumour cell adhesive properties, providing protection from immune elimination and, through their intricate interactions, selecting tumour cells with a metastatic phenotype. Future studies might show that the multitude of growth factors and cytokines released from platelet granules also directly affect tumour cell survival and proliferation, and the recruitment of inflammatory cells into the microenvironment of nascent metastatic lesions. Thus, investigation of platelets, their surface receptors, released products and their critical influence on coagulation pathways, will help to elucidate the mechanisms of tumour metastasis, as well as vascular development and stability, that support metastatic growth.
The changing requirements of disseminating tumour cells during metastasis provide challenging questions to address and understand the complexity of platelet involvement in different stages of cancer progression. Transgenic mouse models with defined aberrations in platelet and other host cell-type functions will help to further elucidate crucial molecular mechanisms. For example, one such model that has not been explored in the context of metastasis is a model of Glanzmann's thrombasthenia 136 . This model recapitulates a human disease in which platelets lack or have aberrant expression of integrin αIIbβ3. Models like this offer the opportunity to explore the contribution of platelet receptors and functions that are key to platelet adhesion, aggregation and activation.
There are several important questions to be addressed: which stages of tumour progression are affected by platelet haemostatic functions? When are platelet adhesive functions important to support or influence tumour progression? When and how is platelet involvement in inflammatory functions crucial? new concepts include the identification and properties of premetastatic niches, and how platelets might contribute to their development in distant organs. Platelet functions during the recruitment of bone marrow progentior cells may be involved 34, 47 . The development of megakaryocyte lineage-specific mouse models will help to delineate platelet contributions, among those of other haematopoietic cells, during the progression of cancer and the establishment of metastatic disease. 
